FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Resources - All Kinds, Realm US, Authority Hl7

19,235 resources

Type: Text:

By Version

 

Start Prev Rows 11400 - 11600 Next

PackageVersionIdentityName/TitleStatusFMMWGDate
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.214.jsonNon Invasive Oxygen Therapy Devicesactive2024-01
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.216.jsonProcedural Hospital Locationsactive2023-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.217.jsonASA physical status classactive2023-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.218.jsonBlood urea nitrogen lab testactive2025-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.219.jsonHemoglobin lab testactive2025-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.22.jsonAnticoagulants for All Indicationsactive2022-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.220.jsonSmoking statusactive2024-01
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.221.jsonAlbumin lab testactive2023-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.222.jsonLeukocyte count lab testactive2024-01
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.223.jsonBilirubin lab testactive2025-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.224.jsonAspartate transaminase lab testactive2023-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.226.jsonCardiac Arrestactive2024-01
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.230.jsonPO Antibacterialsactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.231.jsonInjectable Antifungalsactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.24.jsonMalignant Bone Diseaseactive2022-10
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.242.jsonHeart and Lung Transplantsactive2024-01
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.243.jsonHeart and Lung Transplantsactive2024-01
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.245.jsonLung Resections and Excisionsactive2024-01
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.246.jsonLung Resections and Excisionsactive2024-01
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.247.jsonChest Wall Proceduresactive2024-01
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.248.jsonChest Wall Proceduresactive2024-01
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.249.jsonMaxillary Proceduresactive2024-01
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.250.jsonMaxillary Proceduresactive2024-01
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.251.jsonHead, Neck, and Thoracic Surgeries with High Risk Airway Compromiseactive2024-01
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.252.jsonAnesthesia Requiring Monitored Careactive2024-01
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.253.jsonAnesthesia Requiring Monitored Careactive2024-01
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.255.jsonAnesthesia Requiring Monitored Careactive2024-01
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.256.jsonOsteoporosisactive2025-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.260.jsonRivaroxaban Anticoagulantactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.262.jsonFondaparinux Anticoagulantactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.263.jsonDalteparin Anticoagulantactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.264.jsonHeparinactive2024-01
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.268.jsonEnoxaparin Anticoagulantactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.271.jsonUndetectable Lab Result Valueactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.272.jsonUndetectable Lab Result Valueactive2024-10
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.274.jsonDietary Recommendationsactive2025-01
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.275.jsonBariatric Proceduresactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.276.jsonTelemedicine Servicesactive2025-01
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.277.jsonProstate Cancer Treatmentactive2025-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.28.jsonTraumatic Avulsion of Kidneyactive2022-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.29.jsonRapidly Progressive Nephritic Syndromeactive2023-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.301.jsonLDL Cholesterolactive2025-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.33.jsonObstetrics and VTE Obstetricsactive2022-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.34.jsonGlucose Lab Test Mass Per Volumeactive2023-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.349.jsonTuberculosis for Urology Careactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.350.jsonTuberculosis for Urology Careactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.351.jsonTuberculosis for Urology Careactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.352.jsonAndrogen Deprivation Therapy for Urology Careactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.353.jsonBacillus Calmette Guerin for Urology Careactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.354.jsonBladder Cancer for Urology Careactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.355.jsonChemotherapy Agents for Advanced Canceractive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.356.jsonCystectomy for Urology Careactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.357.jsonCystectomy for Urology Careactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.358.jsonCystectomy for Urology Careactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.359.jsonDEXA Bone Density for Urology Careactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.360.jsonHospital Services for Urology Careactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.361.jsonImmunocompromised Conditionsactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.362.jsonImmunocompromised Conditionsactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.363.jsonImmunocompromised Conditionsactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.364.jsonImmunosuppressive Drugs for Urology Careactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.365.jsonMixed Histology Urothelial Cell Carcinoma for Urology Careactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.366.jsonMorbid Obesityactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.367.jsonMorbid Obesityactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.368.jsonMorbid Obesityactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.369.jsonUnavailability of Bacillus Calmette Guerin for Urology Careactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.370.jsonUrinary Retentionactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.371.jsonUrinary Retentionactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.372.jsonUrinary Retentionactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.374.jsonFace to Face Interactionactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.375.jsonFace to Face Interactionactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.376.jsonHIV Viral Load Testsactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.377.jsonHIV Viral Load Testsactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.389.jsonSyphilis Testsactive2025-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.4.jsonNephrectomyactive2023-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1248.8.jsonLarge Body Surface Area (BSA) Burnsactive2022-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1250.2.jsonPsychological Neuropsychological or Neurobehavioral Testingactive2023-11
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1250.3.jsonPsychological or Neuropsychological Testingactive2023-11
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1251.10.jsonTricuspid Valve Regurgitationactive2023-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1251.2.jsonValvular Heart Diseaseactive2022-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1258.1.jsonGonorrhea Screeningactive2025-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1258.2.jsonAbnormal Weight Lossactive2024-10
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1259.2.jsonPrescribable brand and generic non insulin drugs for hyperglycemia in Type 2 Diabetesactive2023-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1259.3.jsonPrescribable brand and generic insulins and analoguesactive2023-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1259.4.jsoneGFR Using 2021 Race Free Formulasactive2023-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1259.5.jsonFructosamine in Serum or Plasmaactive2023-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1259.6.jsonGlucose tests in venous blood, capillary blood, serum/plasma for Diabetesactive2023-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1259.7.jsonCreatinine in serum/plasmaactive2023-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1259.9.jsonIgE Agonists, prescribableactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.10.jsonEstrogen Receptor Testing for Orserduactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.100.jsonMMR Proficientactive2024-01
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.101.jsonSystemic Cancer Directed Therapyactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.102.jsonFace To Face Interactionactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.104.jsonErdafitinibactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.107.jsonChemotherapy Encounteractive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.108.jsonUrothelial Cancers ICD9active2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.109.jsonUrothelial Cancer ICD10active2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.110.jsonUrothelial Cancersactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.111.jsonPrior Therapies for Erdafitinibactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.112.jsonUrothelial Cancer Histologiesactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.113.jsonMalignant Tumor Behavioractive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.114.jsonLocalized Bladder Cancer Stage SNOMEDactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.116.jsonLocalized Bladder Cancer Stagingactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.117.jsonAdvanced Bladder Cancer Stageactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.118.jsonLocalized Bladder Cancer T Stageactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.119.jsonLocalized Bladder Cancer T Stageactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.120.jsonLocalized Bladder Cancer N Stageactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.121.jsonLocalized Bladder Cancer M Stageactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.122.jsonAdvanced Bladder Cancer M Stageactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.124.jsonLocoregional Urothelial Cancer ICD9active2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.125.jsonLocoregional Urothelial Cancer ICD10active2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.126.jsonLocoregional Urothelial Cancer SNOMEDactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.127.jsonLocoregional Urothelial Canceractive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.128.jsonFGFR3 Geneactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.129.jsonFGFR3 Gene Interpretation Positive SNOMEDactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.130.jsonFGFR3 Gene Interpretation Positive LOINCactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.131.jsonFGFR3 Gene Interpretation Positive NCIactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.133.jsonFGFR3 Gene Interpretation Positiveactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.134.jsonFGFR3 Gene Interpretation Negative SNOMEDactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.135.jsonFGFR3 Gene Interpretation Negative NCIactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.137.jsonFGFR3 Gene Interpretation Negativeactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.138.jsonFGFR3 Molecular Variantsactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.139.jsonTumor Behavioractive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.140.jsonPhyscological Support for Canceractive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.141.jsonReferral For Pain From Canceractive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.142.jsonCancer Pain Educationactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.143.jsonTelehealth Encountersactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.144.jsonPain Assessment Scoreactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.146.jsonTelehealth Encounters SNOMEDCTactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.147.jsonTelehealth Encounters CPTactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.148.jsonTelehealth Encounters HCPCSactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.149.jsonTelehealth Encounters Allactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.150.jsonChemo Admin SNOMEDCTactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.151.jsonChemo Admin CPTactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.152.jsonChemo Admin HCPCSactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.153.jsonChemotherapy Administration Allactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.154.jsonRadiation Treatment CPTactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.155.jsonRadiation Treatment HCPCSactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.156.jsonRadiation Treatment SNOMEDCTactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.157.jsonRadiation Treatment Allactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.158.jsonBipolar Diagnosis Codesactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.159.jsonTelephone Visits SNOMEDactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.160.jsonTelephone Visit CPTactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.161.jsonTelephone Visits Allactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.162.jsonAdolescent depression screening assessmentactive2024-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.163.jsonAdult depression screening assessment LOINCactive2024-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.165.jsonReferral for Depression Adultactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.166.jsonReferrals for Adolescent Depressionactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.167.jsonFollow Ups for Adolescent Depressionactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.168.jsonFollowUps for Adult Depressionactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.169.jsonDepression Screen Declined for Medical Reasonactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.170.jsonPhysical Therapy Evaluations SNOMEDCTactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.171.jsonPhysical Therapy Evaluation CPTactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.172.jsonPhysical Therapies Evaluationsactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.173.jsonNon Opioid Analgesicsactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.174.jsonAdjuvant Analgesicsactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.176.jsonLung Cancer ICD9active2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.177.jsonLung Cancer ICD10active2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.178.jsonLung Canceractive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.179.jsonPrior Therapies for Osimertinibactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.18.jsonStage IAactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.181.jsonPlan of Care for Painactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.182.jsonAll Antineoplastic Agentsactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.183.jsonLocally Advanced NSCLC Stage Groupactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.185.jsonLocalized NSCLC Stage Group SNOMEDactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.186.jsonRadiation Treatment Managementactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.187.jsonPlan of Careactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.188.jsonDocumentation of Plan of Careactive2024-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.189.jsonPain Presentactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.19.jsonStage IBactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.190.jsonLocalized NSCLC Stage Group NCIMactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.192.jsonLocalized NSCLC Stage Groupactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.193.jsonAdvanced NSCLC Stage Groupactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.194.jsonNSCLC M Stage (metastatic)active2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.195.jsonNSCLC T Stageactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.196.jsonNSCLC N Stageactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.197.jsonSCLC and rarer lung cancer histologyactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.198.jsonEGFR Geneactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.199.jsonEGFR Gene Interpretation Positive SNOMEDactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.20.jsonStage IIAactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.200.jsonEGFR Gene Interpretation Positive LOINCactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.201.jsonEGFR Gene Interpretation Positiveactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.202.jsonEGFR Osimertinib Molecular Variantsactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.203.jsonEGFR Generic Molecular Variant NCIMactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.204.jsonEGFR Generic Molecular Variant SNOMEDactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.205.jsonEGFR Generic Molecular Variant LOINCactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.206.jsonEGFR Molecular Variants Osimertinib PMactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.207.jsonOsimertinibactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.208.jsonPemetrexedactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.209.jsonRadiation Treatment Management SNOMEDCTactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.21.jsonStage IIBactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.210.jsonRadiation Treatment Management Codesactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.211.jsonRadiation Treatment Delivery CPTactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.212.json77427 Management Codeactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.213.jsonRadiation Treatment Delivery HCPCSactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.214.jsonRadiation Treatment Delivery NCIMactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.215.jsonRadiation Treatment Delivery SNOMEDactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.216.jsonRadiation Treatment Deliveryactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.217.jsonMET Gene Testactive2024-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.219.jsonTepotinibactive2024-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1260.22.jsonStage IIIAactive2023-08